En caso de embarazo, lactancia o tratamiento mdico, consulte a un profesional sanitario
Translational in vivo and in vitro studies in patient (pts) with acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and myeloproliferative disease (MPD) treated with MK-0457 (MK), a novel Aurora kinase, Flt3, JAK2, and Bcr-Abl inhibitor
[Study abstract] Increase the interval between doses: Another option is to increase the interval between doses to greater than one week
After adjusting for age, body mass index (BMI), disease severity and other health factors, GLP-1 users still showed significantly lower odds of death, suggesting a strong and independent protective effect
Research using these peptides must adhere to appropriate institutional review and safety protocols including proper handling procedures, waste disposal, and experimental design safeguards